Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis

Stroud A 1 , Dhaliwal P 2 , Alvarado R 2 , Winder MJ 2 , Jonker BP 2 , Grayson JW 2 Show all authors , Hamizan A 3 , Harvey RJ 2 , McCormack A 4

Affiliations 

  • 1 Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. stroudanna@outlook.com
  • 2 Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia
  • 3 Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • 4 St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia
Pituitary, 2020 Oct;23(5):595-609.
PMID: 32691356 DOI: 10.1007/s11102-020-01066-8

Abstract

PURPOSE: Transsphenoidal surgery (TSS) is the first-line treatment for Cushing's disease (CD). This review aimed to synthesize the remission and recurrence rates following TSS for CD and identify predictors of these outcomes.

METHODS: Medline (1946-) and Embase (1947-) were searched until 23rd January 2019 for original studies. A meta-analysis was performed of remission and recurrence rates. Studies were excluded if patients had prior radiosurgery/radiotherapy, mixed pathologies or interventions without separated data, follow-up not reported or population size 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications